Vermont Breast Cancer Molecular Characterization Laboratory

佛蒙特州乳腺癌分子表征实验室

• 批准号: 9334814
• 负责人: Brian L Sprague
• 金额: $ 74.13万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-09 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9334814
• 关键词: Address; Adoption; Advisory Committees; Age; Archives; Behavior; Breast; Breast Cancer Detection; Breast Cancer Surveillance Consortium; Breast Cancer Treatment; Breast Epithelial Cells; Cancer Biology; Cancer Center; Cells; Characteristics; Clinical; Collaborations; Collection; Complement; Consensus; Critiques; Data; Data Collection; Development; Diagnosis; Disease; Epidemiology; Exhibits; Formalin; Gene Expression; Gene Expression Profile; Genetic Transcription; Goals; Guidelines; Indolent; Interdisciplinary Study; Journals; Laboratories; Lead; Leadership; Lesion; Life; Link; Malignant - descriptor; Malignant Neoplasms; Mammary Gland Parenchyma; Mammography; Medical; Medicine; Methods; Molecular; Molecular Profiling; New England; New York; Newly Diagnosed; Noninfiltrating Intraductal Carcinoma; Organ; Paraffin Embedding; Pathology; Patients; Play; Population; Population Research; Preventive service; Primary Neoplasm; Procedures; Radiology Specialty; Recommendation; Regimen; Registries; Research; Research Personnel; Research Project Grants; Resources; Role; Screening for cancer; Signal Transduction; Site; Specimen; Symptoms; System; Technology; Therapeutic Intervention; Time; Tissues; Treatment outcome; Vermont; Woman; Work; base; biobank; breast cancer diagnosis; breast imaging; breast tumorigenesis; cancer diagnosis; cancer epidemiology; cancer therapy; case control; clinical care; design; experience; innovation; malignant breast neoplasm; member; minimally invasive; mortality; neoplastic; neoplastic cell; new therapeutic target; novel marker; novel strategies; outcome forecast; outcome prediction; population based; precision medicine; predictive signature; programs; prospective; public health relevance; repository; screening; treatment strategy; tumor microenvironment; tumor progression

 DESCRIPTION (provided by applicant): Advances in breast cancer screening and treatment have reduced breast cancer mortality in the US over the past 30 years. However, the widespread adoption of screening mammography has been accompanied by dramatic increases in early stage breast cancer diagnoses that have not been offset by declines in advanced stage disease. Accumulating evidence suggests that a substantial fraction of screen-detected breast cancers would never have emerged clinically if not detected through screening. While there is extensive debate regarding the magnitude of overdiagnosis, there is widespread consensus that new approaches are urgently needed to distinguish indolent screen-detected cases from those that may be life threatening. The role of the tumor microenvironment in breast cancer progression has been increasingly recognized. Several lines of evidence indicate that breast tumorigenesis is critically influenced by active signaling between malignant breast epithelial cells and non-neoplastic cells of the tumor microenvironment. The goal of our proposal is to identify tumor microenvironment signatures that predict the aggressiveness of early stage, screen-detected breast cancers by minimally invasive methods. We will leverage and refine state-of-the-art technologies to characterize aggressive signatures based on the cellular composition and gene expression of specific cell populations within the tumor microenvironment of interval- and symptom-detected invasive breast cancers. We will then determine whether the presence of these aggressive tumor microenvironment signatures in early stage, screen-detected breast cancer is associated with progression. We will obtain retrospective data on 800 formalin-fixed, paraffin-embedded specimens for analysis from the Vermont Breast Cancer Surveillance System (VBCSS), which has collected integrated patient, radiology, pathology, treatment, and outcomes data on all women undergoing breast imaging in the state of Vermont since 1996. The VBCSS has a large existing repository of over 1,200 centrally-reviewed DCIS specimens and access to over 10,000 invasive breast cancer specimens for cases diagnosed in the state of Vermont. We will also engage in prospective collection of fresh specimens via the Vermont Cancer Center Tissue Biobank, which is also linked to the integrated data of the VBCSS. The identification of aggressive and indolent tumor microenvironment signatures will promote the development of more conservative treatment strategies for the subset of women with favorable prognosis and suggest novel targets for therapeutic intervention in cases with unfavorable prognosis. We have assembled a multidisciplinary research team with nationally recognized expertise in cellular and molecular cancer biology, pathology, cancer screening, and epidemiology, as well as a long track record of productive consortium-based collaborative research. The Vermont Breast Cancer Molecular Characterization Laboratory will provide the consortium with scientific leadership, technical resources, and access to a large repository of retrospective and prospectively collected breast specimens linked to the rich data of the VBCSS.

 描述(申请人提供)：在过去的30年里，乳腺癌筛查和治疗的进步降低了美国的乳腺癌死亡率。然而，筛查乳房X光检查的广泛采用伴随着早期乳腺癌诊断的急剧增加，这并没有被晚期疾病的下降所抵消。越来越多的证据表明，如果没有通过筛查发现，很大一部分筛查发现的乳腺癌永远不会出现在临床上。虽然关于过度诊断的严重程度存在广泛的争论，但人们普遍认为，迫切需要新的方法来区分懒惰的筛查发现的病例和可能危及生命的病例。肿瘤微环境在乳腺癌进展中的作用已得到越来越多的认识。一些证据表明，乳腺肿瘤的发生受到肿瘤微环境中恶性乳腺上皮细胞和非肿瘤细胞之间的活跃信号的严重影响。我们建议的目标是确定肿瘤微环境特征，通过微创方法预测早期筛查发现的乳腺癌的侵袭性。我们将利用和改进最先进的技术，根据间隔检测和症状检测的浸润性乳腺癌的肿瘤微环境中特定细胞群体的细胞组成和基因表达来表征侵袭性特征。然后，我们将确定这些侵袭性肿瘤微环境特征的存在是否与早期筛查发现的乳腺癌的进展有关。我们将从佛蒙特州乳腺癌监测系统(VBCS)获得800个福尔马林固定的石蜡包埋标本的回顾性数据，用于分析，该系统自1996年以来收集了佛蒙特州所有接受乳房成像的女性的综合患者、放射学、病理学、治疗和结果数据。VBCS现有1,200多个经中央审查的DCIS样本，以及佛蒙特州确诊病例的10,000多个浸润性乳腺癌样本。我们还将通过佛蒙特州癌症中心组织生物库进行预期的新鲜标本收集，该生物库也与VBCS的综合数据相联系。对侵袭性和惰性肿瘤微环境信号的识别将促进对预后良好的妇女亚群的更保守的治疗策略的发展，并为预后不良的病例提供新的治疗干预靶点。我们组建了一支多学科研究团队，在细胞和分子癌症生物学、病理学、癌症筛查和流行病学方面拥有国家公认的专业知识，并在基于联盟的富有成效的合作研究方面有着长期的记录。佛蒙特州乳腺癌分子表征实验室将为该联盟提供科学领先地位、技术资源，并访问与VBCS丰富数据相联系的大型回溯性和前瞻性收集的乳腺标本存储库。